Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chronocort versus standard glucocorticoid replacement in adults with congenital adrenal hyperplasia
2015-000711-40Phase 3Completed
- Sponsor
- Diurnal Group plc
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of hydrocortisone modified-release in congenital adrenal hyperplasia (CAH) (2 arms), sponsored by Diurnal Group plc. Primary endpoint: Change from baseline to 24 weeks in mean 24-hour standard deviation score profile for 17-hydroxyprogesterone. Started Jul 2015; status: completed.
02
Drugs
hydrocortisone modified-release
03
Conditions
congenital adrenal hyperplasia (CAH)
Beyond the preview
Go deeper on 2015-000711-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000711-40.